MARKET

LPTX

LPTX

Leap Therapeutic
NASDAQ
3.200
-0.010
-0.31%
After Hours: 3.200 0 0.00% 16:00 04/23 EDT
OPEN
3.210
PREV CLOSE
3.210
HIGH
3.330
LOW
3.090
VOLUME
89.02K
TURNOVER
0
52 WEEK HIGH
10.20
52 WEEK LOW
1.235
MARKET CAP
81.92M
P/E (TTM)
-0.8036
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LPTX last week (0415-0419)?
Weekly Report · 1d ago
Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024
Benzinga · 4d ago
GILEAD SCIENCES, INC REPORTS 13.9% PASSIVE STAKE IN LEAP THERAPEUTICS AS OF APRIL 10- SEC FILING
Reuters · 4d ago
Weekly Report: what happened at LPTX last week (0408-0412)?
Weekly Report · 04/15 12:08
Top 10 stocks with upwards and downwards daily percentage change - Piper Sandler
Piper Sandler published the top 10 stocks with upwards and downwards daily percentage change as of Thursday. The S&P 500 (SP500) is vulnerable to a possible 5-10% pullback in upcoming weeks or months, analysts say. High-interest rates, inflation, and mediocre breadth are making the market vulnerable to pullback, Piper Sandler says.
Seeking Alpha · 04/12 15:34
Leap Therapeutics Shares Rise 9% After Pricing of Private Placement
Leap Therapeutics shares were up 9% at $3.31 in recent trading. The stock is down about 20% in the past 12 months. The company entered a securities purchase agreement with a group of institutional investors to issue and sell 12.7 million shares in a private placement.
Dow Jones · 04/11 14:29
Leap Therapeutics To Sell $40 Mln Of Shares In Private Placement; Stock Up Over 14%
NASDAQ · 04/11 13:06
LEAP THERAPEUTICS INC: INTENDS TO USE NET PROCEEDS FROM FINANCING TO FUND CONTINUED DEVELOPMENT OF ITS LEAD MONOCLONAL ANTIBODY PROGRAM, DKN-01
Reuters · 04/11 12:30
More
About LPTX
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Webull offers Leap Therapeutics Inc stock information, including NASDAQ: LPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LPTX stock methods without spending real money on the virtual paper trading platform.